A Deep Learning-Based System Trained for Gastrointestinal Stromal Tumor Screening Can Identify Multiple Types of Soft Tissue Tumors.

Journal: The American journal of pathology
Published Date:

Abstract

The accuracy and timeliness of the pathologic diagnosis of soft tissue tumors (STTs) critically affect treatment decision and patient prognosis. Thus, it is crucial to make a preliminary judgement on whether the tumor is benign or malignant with hematoxylin and eosin-stained images. A deep learning-based system, Soft Tissue Tumor Box (STT-BOX), is presented herein, with only hematoxylin and eosin images for malignant STT identification from benign STTs with histopathologic similarity. STT-BOX assumed gastrointestinal stromal tumor as a baseline for malignant STT evaluation, and distinguished gastrointestinal stromal tumor from leiomyoma and schwannoma with 100% area under the curve in patients from three hospitals, which achieved higher accuracy than the interpretation of experienced pathologists. Particularly, this system performed well on six common types of malignant STTs from The Cancer Genome Atlas data set, accurately highlighting the malignant mass lesion. STT-BOX was able to distinguish ovarian malignant sex-cord stromal tumors without any fine-tuning. This study included mesenchymal tumors that originated from the digestive system, bone and soft tissues, and reproductive system, where the high accuracy of migration verification may reveal the morphologic similarity of the nine types of malignant tumors. Further evaluation in a pan-STT setting would be potential and prospective, obviating the overuse of immunohistochemistry and molecular tests, and providing a practical basis for clinical treatment selection in a timely manner.

Authors

  • Zhu Meng
  • Guangxi Wang
    Beijing University of Posts and Telecommunications and Department of Pathology, Peking University Third Hospital, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Fei Su
    School of Electrical and Information Engineering, Tianjin University, 300072, Tianjin, China. Electronic address: sufei@tju.edu.cn.
  • Yan Liu
    Department of Clinical Microbiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, People's Republic of China.
  • Yuxiang Wang
    Hefei Ion Medical Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui, China.
  • Jing Yang
    Beijing Novartis Pharma Co. Ltd., Beijing, China.
  • Jianyuan Luo
    Department of Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Fang Cao
    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Panpan Zhen
    Department of Pathology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Binhua Huang
    Department of Pathology, Dongguan Houjie Hospital, Dongguan, China.
  • Yuxin Yin
    Beijing University of Posts and Telecommunications and Department of Pathology, Peking University Third Hospital, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Zhicheng Zhao
  • Limei Guo
    Beijing University of Posts and Telecommunications and Department of Pathology, Peking University Third Hospital, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. Electronic address: guolimei@bjmu.edu.cn.